Key Points
- CEO August Troendle sold 16,083 Medpace shares at an average price of $628.64, generating about $10.1 million. His remaining stake was 417,289 shares, a 3.71% reduction.
- Medpace reported strong quarterly results, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year. Fiscal 2026 EPS guidance is $17.25–$17.95.
- MEDP opened at $618.88, while analysts held a consensus “Hold” rating and an average price target of $595.20; institutional investors own approximately 77.98% of the stock.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 16,083 shares of Medpace stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $628.64, for a total transaction of $10,110,417.12. Following the completion of the sale, the chief executive officer owned 417,289 shares of the company's stock, valued at $262,324,556.96. This trade represents a 3.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Medpace Stock Down 0.3%
Shares of NASDAQ MEDP opened at $618.88 on Friday. The business's 50 day moving average is $594.65 and its two-hundred day moving average is $515.99. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market cap of $17.27 billion, a price-to-earnings ratio of 36.28, a PEG ratio of 2.77 and a beta of 1.15.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Institutional Trading of Medpace
Several hedge funds have recently modified their holdings of the stock. State Street Corp increased its holdings in Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company's stock worth $376,483,000 after purchasing an additional 28,666 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Medpace by 38.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company's stock valued at $10,615,000 after buying an additional 5,610 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Medpace by 8.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company's stock valued at $587,000 after buying an additional 84 shares during the period. Tidal Investments LLC grew its position in shares of Medpace by 8.0% during the second quarter. Tidal Investments LLC now owns 6,155 shares of the company's stock worth $3,260,000 after buying an additional 458 shares in the last quarter. Finally, Archford Capital Strategies LLC grew its position in shares of Medpace by 5.4% during the second quarter. Archford Capital Strategies LLC now owns 1,658 shares of the company's stock worth $878,000 after buying an additional 85 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have weighed in on MEDP. Mizuho lifted their target price on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. BMO Capital Markets raised their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Finally, Weiss Ratings upgraded shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of "Hold" and an average target price of $595.20.
Read Our Latest Stock Analysis on MEDP
About Medpace
(
Get Free Report)
Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
